LeMaitre Vascular Revenue 2007-2019 | LMAT

LeMaitre Vascular revenue from 2007 to 2019. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
LeMaitre Vascular Annual Revenue
(Millions of US $)
2018 $106
2017 $101
2016 $89
2015 $78
2014 $71
2013 $65
2012 $57
2011 $58
2010 $56
2009 $51
2008 $49
2007 $41
2006 $35
2005 $31
LeMaitre Vascular Quarterly Revenue
(Millions of US $)
Q1 2019 $28
Q4 2018 $28
Q3 2018 $24
Q2 2018 $27
Q1 2018 $26
Q4 2017 $26
Q3 2017 $25
Q2 2017 $26
Q1 2017 $24
Q4 2016 $23
Q3 2016 $23
Q2 2016 $22
Q1 2016 $20
Q4 2015 $20
Q3 2015 $19
Q2 2015 $20
Q1 2015 $19
Q4 2014 $19
Q3 2014 $18
Q2 2014 $18
Q1 2014 $17
Q4 2013 $18
Q3 2013 $15
Q2 2013 $16
Q1 2013 $15
Q4 2012 $15
Q3 2012 $14
Q2 2012 $14
Q1 2012 $14
Q4 2011 $13
Q3 2011 $15
Q2 2011 $15
Q1 2011 $15
Q4 2010 $14
Q3 2010 $14
Q2 2010 $14
Q1 2010 $14
Q4 2009 $14
Q3 2009 $13
Q2 2009 $13
Q1 2009 $11
Q4 2008 $12
Q3 2008 $12
Q2 2008 $13
Q1 2008 $12
Q4 2007 $11
Q3 2007 $10
Q2 2007 $10
Q1 2007 $10
Q4 2006 $0
Q2 2006 $9
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $0.516B $0.106B
LeMaitre Vascular, Inc. is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects the people worldwide. LeMaitre develops, manufactures, and markets disposable and implantable vascular devices to address the needs of vascular surgeons and interventionalists. LeMaitre's diversified product portfolio consists of twelve well-known brand name products used in arteries and veins outside of the heart and are supported by a growing, specialized and highly trained organization of vascular sales professionals. LeMaitre Vascular offers a wide range of innovative products to vascular surgeons and interventionalists for improving procedure efficacy and minimizing patient recovery time.
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $144.751B 28.10
Medtronic (MDT) Ireland $130.521B 18.64
Stryker (SYK) United States $73.274B 26.15
Boston Scientific (BSX) United States $56.572B 27.12
Baxter (BAX) United States $40.227B 25.35
Zimmer Biomet Holdings (ZBH) United States $24.111B 15.49
Smith & Nephew SNATS (SNN) United Kingdom $18.903B 0.00
ResMed (RMD) United States $16.992B 32.47
Canopy Growth (CGC) Canada $14.424B 0.00
Bio-Rad Laboratories (BIO) United States $9.006B 47.74
Aurora Cannabis (ACB) Canada $7.707B 76.00
Hill-Rom Holdings (HRC) United States $7.016B 21.27
Insulet (PODD) United States $6.948B 506.22
Perrigo (PRGO) Ireland $5.950B 10.06
Haemonetics (HAE) United States $5.808B 47.41
GW Pharmaceuticals (GWPH) United Kingdom $5.137B 0.00
ICU Medical (ICUI) United States $4.924B 29.38
Hutchison China MediTech (HCM) China $3.540B 0.00
Neogen (NEOG) United States $3.243B 52.74
NuVasive (NUVA) United States $2.986B 24.38
Agios Pharmaceuticals (AGIO) United States $2.974B 0.00
National Vision Holdings (EYE) United States $2.384B 50.80
Quidel (QDEL) United States $2.278B 23.65
Aphria (APHA) $1.722B 0.00
Cardiovascular Systems (CSII) United States $1.456B 836.40
HEXO (HEXO) $1.415B 0.00
Phibro Animal Health (PAHC) United States $1.170B 17.53
AtriCure (ATRC) United States $1.155B 0.00
VAREX IMAGING (VREX) United States $1.080B 22.93
Lantheus Holdings (LNTH) United States $1.042B 27.66
OrganiGram Holdings (OGI) Canada $0.963B 0.00
NanoString Technologies (NSTG) United States $0.926B 0.00
PetIQ (PETQ) United States $0.871B 21.15
Quanterix (QTRX) United States $0.852B 0.00
Omeros (OMER) United States $0.830B 0.00
MacroGenics (MGNX) United States $0.784B 0.00
Eagle Pharmaceuticals (EGRX) United States $0.737B 20.67
TG Therapeutics (TGTX) United States $0.656B 0.00
Cerus (CERS) United States $0.656B 0.00
Surmodics (SRDX) United States $0.551B 80.16
OraSure Technologies (OSUR) United States $0.534B 24.60
Meridian Bioscience (VIVO) United States $0.498B 15.21
Evolus (EOLS) United States $0.381B 0.00
Vapotherm (VAPO) United States $0.363B 0.00
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.351B 0.00
BioLife Solutions (BLFS) United States $0.332B 103.94
Zynex (ZYXI) United States $0.306B 31.67
Utah Medical Products (UTMD) United States $0.299B 20.72
Rockwell Medical (RMTI) United States $0.254B 0.00
Bovie Medical (APYX) United States $0.226B 0.00
Cytosorbents (CTSO) United States $0.213B 0.00
Owens & Minor (OMI) United States $0.181B 3.84
Chimerix (CMRX) United States $0.181B 0.00
Fonar (FONR) United States $0.135B 7.11
Female Health (VERU) United States $0.129B 0.00
Chembio Diagnostics (CEMI) United States $0.098B 0.00
BRAINSWAY LTD (BWAY) Israel $0.097B 0.00
InfuSystems Holdings (INFU) United States $0.092B 0.00
Surface Oncology (SURF) United States $0.090B 0.00
United-Guardian (UG) United States $0.087B 19.02
Neurotrope (NTRP) United States $0.082B 0.00
Oramed Pharmaceuticals (ORMP) United States $0.062B 0.00
ImmuCell (ICCC) United States $0.048B 0.00
Trinity Biotech (TRIB) Ireland $0.041B 14.17
Senestech (SNES) United States $0.037B 0.00
GUARDION HEALTH (GHSI) United States $0.032B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.024B 0.00
Insys Therapeutics (INSY) United States $0.022B 0.00
Cellectar Biosciences (CLRB) United States $0.021B 0.00
Valeritas Holdings (VLRX) United States $0.017B 0.00
Myomo (MYO) United States $0.014B 0.00
Capricor Therapeutics (CAPR) United States $0.011B 0.00
Akers Biosciences Inc (AKER) United States $0.007B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.007B 0.00
NeuroMetrix (NURO) United States $0.005B 3.82